Crinetics Pharmaceuticals Inc (CRNX) to Post FY2019 Earnings of ($2.38) Per Share, Cantor Fitzgerald Forecasts

Share on StockTwits

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) – Analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, March 12th. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings per share of ($2.38) for the year. Cantor Fitzgerald has a “Overweight” rating and a $40.00 price objective on the stock.

Separately, HC Wainwright began coverage on shares of Crinetics Pharmaceuticals in a report on Thursday, February 14th. They set a “buy” rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $37.20.

Crinetics Pharmaceuticals stock opened at $25.00 on Friday. Crinetics Pharmaceuticals has a 52-week low of $19.23 and a 52-week high of $42.00.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. The business had revenue of $0.78 million during the quarter, compared to analyst estimates of $0.32 million. Crinetics Pharmaceuticals had a negative net margin of 972.23% and a negative return on equity of 78.81%.

Institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its stake in shares of Crinetics Pharmaceuticals by 0.7% in the 4th quarter. Northern Trust Corp now owns 76,727 shares of the company’s stock valued at $2,301,000 after acquiring an additional 498 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at $30,000. New York State Common Retirement Fund bought a new stake in shares of Crinetics Pharmaceuticals in the 4th quarter valued at $123,000. American International Group Inc. bought a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at $132,000. Finally, Bank of America Corp DE increased its stake in shares of Crinetics Pharmaceuticals by 377.2% in the 4th quarter. Bank of America Corp DE now owns 5,932 shares of the company’s stock valued at $179,000 after acquiring an additional 4,689 shares in the last quarter. Hedge funds and other institutional investors own 69.86% of the company’s stock.

In other Crinetics Pharmaceuticals news, major shareholder Ventures Iv L.P. 5Am sold 262,153 shares of the firm’s stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $21.88, for a total transaction of $5,735,907.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Featured Story: What is Depreciation?

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Public Employees Retirement Association of Colorado Purchases 13,418 Shares of Philip Morris International Inc.
Public Employees Retirement Association of Colorado Purchases 13,418 Shares of Philip Morris International Inc.
BMO Capital Markets Boosts Hexcel  Price Target to $84.00
BMO Capital Markets Boosts Hexcel Price Target to $84.00
Catabasis Pharmaceuticals  Downgraded to Hold at Zacks Investment Research
Catabasis Pharmaceuticals Downgraded to Hold at Zacks Investment Research
Chubb  Price Target Raised to $167.00
Chubb Price Target Raised to $167.00
Hewlett Packard Enterprise  Upgraded to “Buy” by Zacks Investment Research
Hewlett Packard Enterprise Upgraded to “Buy” by Zacks Investment Research
Everest Re Group  Price Target Increased to $285.00 by Analysts at Barclays
Everest Re Group Price Target Increased to $285.00 by Analysts at Barclays


© 2006-2019 Ticker Report